January 17, 2017 09:00 AM EST

Lagging further behind, AstraZeneca adds fresh details to its checkpoint comeback strategy

John Carroll

Editor & Founder

AstraZeneca has sketched out some fresh details on its mission critical pivotal study on its checkpoint drug approach to non-small cell lung cancer, mapping …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lagging further behind, AstraZeneca adds fresh details to its checkpoint comeback strategy

John Carroll

Editor & Founder

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Lag­ging fur­ther be­hind, As­traZeneca adds fresh de­tails to its check­point come­back strat­e­gy

Editor & Founder

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Lagging further behind, AstraZeneca adds fresh details to its checkpoint comeback strategy